Predialysis chronic kidney disease: Evaluation of quality of life in clinic patients receiving comprehensive anemia care

Research in Social and Administrative Pharmacy

Volumn 5, Issue 2, 2009, Pages 143-153

  Hansen, Richard A ^a   Chin, Hyunsook ^b   Blalock, Susan ^a   Joy, Melanie S ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Chronic kidney disease; KDQOL; Multidisciplinary; Quality of life; SF 36

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MALE; METABOLISM; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRE; SLEEP; SOCIAL BEHAVIOR;

ADULT; AGED; ANEMIA; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SLEEP; SOCIAL BEHAVIOR;

EID: 67349176047     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2008.06.004     Document Type: Article

References (31)

1. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) S1-S266
3. Marsh J.T., Brown W.S., Wolcott D., et al. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39 (1991) 155-163
4. Goicoechea M., de Vinuesa S.G., Gómez-Campderá F., and Luño J. Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int Suppl 93 (2005 Jan) S35-S38
5. Jurkovitz C.T., Abramson J.L., Vaccarino L.V., Weintraub W.S., and McClellan W.M. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 14 (2003) 2919-2925
6. Foley R.N. Anaemia: cardiovascular adaptations and maladaptive responses in chronic kidney disease. Nephrol Dial Transplant 17 Suppl 11 (2002) 32-34
7. Evans R.W., Rader B., and Manninen D.L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 263 (1990) 825-830
8. Collins A.J., Roberts T.L., St Peter W.L., Chen S.C., Ebben J., and Constantini E. United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis 39 (2002) 784-795
9. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 (2006) S11-S145
10. United States Renal Data System. USRDS 2005 Annual Data Report (2005), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
11. Joy M.S., Candiani C., Vaillancourt B.A., Chin H., Hogan S.L., and Falk R.J. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease. Pharmacotherapy 27 (2007) 734-744
12. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
13. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Information on erythropoiesis stimulating agents (ESA) (marketed as Procrit, Epogen, and Aranesp). FDA Alert 11/8/2007. Available at: http://www.fda.gov/cder/drug/infopage/RHE/default.htm. Accessed 12.12.07.
14. Hays R.D., Kallich J.D., Mapes D.L., Coons S.J., and Carter W.B. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 3 (1994) 329-338
15. Alexander M., Kewalramani R., Agodoa I., and Globe D. Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin 23 (2007) 2997-3008
16. Abu-Alfa A.K., Sloan L., Charytan C., et al. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin 24 (2008) 1091-1100
17. Cronbach L.J. Coefficient alpha and the internal structure of tests. Psychometrika 16 (1951) 297-334
18. Hays RD, Kallich JD, Mapes DL, et al. Kidney Disease Quality of Life Short Form (KDQOL-SF), Version 1.3: A Manual for Use and Scoring. RAND, Santa Monica, CA; 1997.
19. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
20. Hays R.D., Sherbourne C.D., and Mazel R.M. The RAND 36-Item Health Survey 1.0. Health Econ 2 (1993) 217-227
21. McHorney C.A., Ware Jr. J.E., Rogers W., Raczek A.E., and Lu J.F. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care 30 (1992) MS253-MS265
22. McHorney C.A., Ware Jr. J.E., and Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31 (1993) 247-263
23. Fukuhara S., Lopes A.A., Bragg-Gresham J.L., et al. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 64 (2003) 1903-1910
24. Manns B., Johnson J.A., Taub K., Mortis G., Ghali W.A., and Donaldson C. Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants?. Clin Nephrol 60 (2003) 341-351
25. Perlman R.L., Finkelstein F.O., Liu L., et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 45 (2005) 658-666
26. McHorney C.A., Kosinski M., and Ware Jr. J.E. Comparisons of the costs and quality of norms for the SF-36 health survey collected by mail versus telephone interview: results from a national survey. Med Care 32 (1994) 551-567
27. National Kidney Foundation. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 37 (2001) S182-S238
28. Gorodetskaya I., Zenios S., McCulloch C.E., et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 68 (2005) 2801-2808
29. Unruh M., Miskulin D., Yan G., et al. Racial differences in health-related quality of life among hemodialysis patients. Kidney Int 65 (2004) 1482-1491
30. Revicki D.A., Brown R.E., Feeny D.H., et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (1995) 548-554
31. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098